New drug cocktail targets tough lung cancer mutation
Disease control
Completed
This phase 2 trial tested a combination of two oral drugs, RMC-4630 and sotorasib, in 47 adults with advanced KRASG12C-mutant non-small cell lung cancer that had progressed after standard treatments. The goal was to see if the combination could shrink tumors. The study is now com…
Phase: PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC